Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Chinese Patent Office
Cipla
Dow
Fish and Richardson
Fuji
UBS
Mallinckrodt
Argus Health
Deloitte

Generated: January 18, 2018

DrugPatentWatch Database Preview

ILUVIEN Drug Profile

« Back to Dashboard

When do Iluvien patents expire, and when can generic versions of Iluvien launch?

Iluvien is a drug marketed by Alimera Sciences Inc and is included in one NDA. There are five patents protecting this drug.

This drug has one hundred and eighty-three patent family members in twenty-six countries.

The generic ingredient in ILUVIEN is fluocinolone acetonide. There are twelve drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the fluocinolone acetonide profile page.
Summary for ILUVIEN
Drug patent expirations by year for ILUVIEN
Pharmacology for ILUVIEN
Medical Subject Heading (MeSH) Categories for ILUVIEN

US Patents and Regulatory Information for ILUVIEN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alimera Sciences Inc ILUVIEN fluocinolone acetonide IMPLANT;INTRAVITREAL 201923-001 Sep 26, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Alimera Sciences Inc ILUVIEN fluocinolone acetonide IMPLANT;INTRAVITREAL 201923-001 Sep 26, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Alimera Sciences Inc ILUVIEN fluocinolone acetonide IMPLANT;INTRAVITREAL 201923-001 Sep 26, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Alimera Sciences Inc ILUVIEN fluocinolone acetonide IMPLANT;INTRAVITREAL 201923-001 Sep 26, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Alimera Sciences Inc ILUVIEN fluocinolone acetonide IMPLANT;INTRAVITREAL 201923-001 Sep 26, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Alimera Sciences Inc ILUVIEN fluocinolone acetonide IMPLANT;INTRAVITREAL 201923-001 Sep 26, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for ILUVIEN

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,192,579 Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof ➤ Subscribe
7,439,249 Inhibitors of phosphatases ➤ Subscribe
8,574,613 Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof ➤ Subscribe
9,566,336 In situ gelling drug delivery system ➤ Subscribe
8,815,284 Bioerodible sustained release drug delivery systems ➤ Subscribe
8,574,659 Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for ILUVIEN

Supplementary Protection Certificates for ILUVIEN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2014000063 Germany ➤ Subscribe PRODUCT NAME: FLUOCINOLONACETONID; NAT. REGISTRATION NO/DATE: 82809.00.00 20120720; FIRST REGISTRATION: GB PL 27813/0001 20120504
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Covington
Accenture
Merck
Deloitte
Cantor Fitzgerald
Colorcon
Fish and Richardson
US Department of Justice
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot